Track topics on Twitter Track topics that are important to you
AIX-EN-PROVENCE, FRANCE -- (Marketwired) -- 07/21/15 -- SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814, PEA-PME eligible)
Unaudited data NB (*): this revenue is non-recurrent by nature and is not part of the Group's core business.
Jérôme Destoppeleir, SuperSonic Imagine's Chief Financial Officer, comments: "Asia, and China in particular, where revenue was up +124% over the first half of the year, represents the Group's main growth area. The strong momentum recorded in Asia is continuing thanks to China, which accounted for 28% of our total sales through June 30, 2015 compared to 13% for the same period last year, and to Japan, which has seen a solid performance just months after regulatory approval was granted in that country. Sales in the United States have fallen short of expectations, and have led us to implement a more efficient commercial strategy there by investing more substantially in our direct sales force, which will also enable us to improve further our margins. In Europe, Germany recorded a good first half thanks to the performance of its direct sales network. In France, there has been a market shift compared to last year which impacted Q1 volume negatively. Corrective actions are already showing early positive results. Our differentiated clinical solutions are continuing to gain momentum, especially in the Liver and Breast domains."
In the first half of 2015, SuperSonic Imagine recorded revenue of EUR 8.3 million, an increase of +2% compared with the first half of 2014 (EUR 8.1 million). At constant currency, there would have been a -6% decrease between the 2 periods. Q2 2015 saw a slight fall of -3% in revenue to EUR 5.0 million (compared with 5.2 million and -11% at constant currency), following a Q1 2015 that saw sales increase by +11% to EUR 3.2 million (vs. EUR 2.9 million and +2% at constant currency). This under-performance was essentially due to the ongoing commercial transition in the United States and the weaker contribution of indirect sales in the distribution mix in this area.
In the first half, SuperSonic Imagine confirmed its strong growth dynamic in Asia, which accounted for 43% of total sales over the first half of the year. Comparatively, the EMEA and Americas zones accounted for 37% and 20% of total sales respectively. Over the first half of 2015, the services revenues grew at 13% and are now 10% of sales against 9% a year ago.
Other revenue comes essentially from access to the Group's technology. This non-recurrent revenue is not written down as sales as it is not part of its core activity.
Next press release: 1H 2015 results will be published on September 14, 2015
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.
For more information about SuperSonic Imagine, please go to www.supersonicimagine.comMarketing & Communication Emmanuelle Vella +33 4 86 79 03 27 Investor Relations - US Candice Knoll +1 415 375 3340 Ext. 105 Investor Relations - EU Pierre Laurent / Florent Alba +33 1 44 71 98 55 Media Relations Adelaide Manester +33 1 58 18 32 58 / +33 6 70 45 74 37 NEXT ARTICLE
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...